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ABSTRACT
Introduction The incidence and mortality rates of 
cutaneous melanoma (CM) are increasing among fair-
skinned populations worldwide. Ultraviolet radiation (UVR) 
is the principal risk factor for CM, but is also the main 
source of 25-hydroxyvitamin D (25(OH)D), which has been 
associated with reduced risk and better prognosis of some 
cancer types. However, both low and high 25(OH)D levels 
have been associated with increased risk of CM. Obesity 
as measured by body mass index (BMI) is associated with 
risk of several cancers and has also been suggested as a 
risk factor for CM, and may also be related to insufficient 
25(OH)D and/or high leptin levels. Moreover, contracting a 
CM diagnosis has been associated with increased risk of 
developing second cancer. We aim to study whether low 
prediagnostic serum levels of 25(OH)D, high prediagnostic 
levels of BMI and high serum leptin levels influence CM 
incidence, Breslow thickness and CM mortality, and risk of 
second cancer and survival after a CM diagnosis.
Methods and analysis Cohort and nested case–control 
studies will be carried out using the population-based 
Janus Serum Bank Cohort (archival prediagnostic sera, 
BMI, smoking and physical activity), with follow-up from 
1972 to 2014. Additional data will be received from the 
Cancer Registry of Norway, the national Cause of Death 
Registry, Statistics Norway (education and occupation) 
and exposure matrices of UVR. Time-to-event regression 
models will be used to analyse the cohort data, while 
the nested case–control studies will be analysed by 
conditional logistic regression. A multilevel approach will 
be applied when incorporating group-level data.
Ethics and dissemination The project is approved by 
the Regional Committee for Medical Research Ethics 
and is funded by the Norwegian Cancer Society. Results 
will be published in peer-reviewed journals, at scientific 
conferences and in the news media.
IntroductIon
rationale and evidence gaps
Ultraviolet radiation (UVR) is a recognised 
human carcinogen and the principal environ-
mental risk factor for cutaneous melanoma 
(CM),1 2 while skin characteristics such as 
skin sensitivity and number of naevi indi-
cate CM susceptibility.3–7 CM incidence and 
mortality rates have been increasing in fair-
skinned populations worldwide the past 
decades, and CM is currently the third most 
common cancer in Europe after cancers of 
the colon/rectum and the lung.8 9 In Norway, 
CM incidence has increased more than 3% 
annually between 1982 and 2011 and has 
been projected to continue to rise.9 Excess 
UVR exposure is likely the major cause of this 
increase,10 but also low vitamin D levels and 
obesity have been suggested to play a role.11 12
Vitamin D synthesis in the skin is initi-
ated by UVR exposure to the skin surface at 
wavelengths of 290–320 nm, which converts 
7-dehydrocholesterol in the keratinocytes to 
previtamin D3 (cholecalciferol). Together 
with previtamin D2 (ergocalciferol), previ-
tamin D3 may also be obtained by diet. Both 
previtamin D2 and D3 are then hydroxyl-
ated in the liver to 25-hydroxyvitamin D 
(25(OH)D), which represents the circu-
lating storage form of vitamin D. A second 
hydroxylation in the kidney converts vitamin 
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Protocol
Strengths and limitations of this study
 ► Linkage of independent, national data sources by 
use of a unique personal identification number for 
a comprehensive research file and complete control 
of loss to follow-up.
 ► Prediagnostic serum samples assuring a true 
prospective relationship between exposures and 
cancer, limiting bias introduced by reverse causality.
 ► Lifetime ambient ultraviolet radiation (UVR) exposure 
data (UVA, UVB and erythemally weighted UV) and 
group-level data on sunburns, sunbathing vacations 
and solarium use capturing variations in age, time 
period and county of residence.
 ► Ambient UVR exposure and data on sunburns, 
sunbathing vacations and solarium use can only be 
linked to the Janus Cohort on a group level.
 ► Lack of data on pigmentary characteristics and 
naevi.
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D to its biologically active form 1, 25-hydroxyvitamin D 
(1, 25(OH)D),13 14 which has been associated with anti-
cancer mechanisms.13 15–17 Based on four studies, a recent 
meta-analysis reported a summary relative risk of CM of 
1.46 (95% CI: 0.60 to 3.53) for the highest compared 
with the lowest (reference) quantile of 25(OH)D.12 In 
three of these studies, risks increased with increasing 
25(OH)D serum levels, while the fourth study reported 
the opposite.18–21 None of these studies individually 
showed any statistically significant associations, and the 
inconclusive results may be due to difference in statistical 
power, the covariate adjustments, whether CM cases had 
a cancer history or not, and whether serum was sampled 
before or after the CM diagnosis. Several recent studies 
have reported an inverse association between Breslow 
thickness and 25(OH)D serum level at diagnosis.20 22–25 
As both tumour thickness and 25(OH)D level were 
measured at the same time in these studies, these asso-
ciations may have been affected by reverse causality.26 27 
However, for prognosis after a CM diagnosis, higher diag-
nostic 25(OH)D levels have been shown to predict lower 
risk of relapse and increased survival, independent of 
Breslow thickness.22 24 A recent study ascribed the effect 
on CM survival to change in 25(OH)D during follow-up 
from CM diagnosis to death, and not the 25(OH)D level 
at diagnosis.28
Low 25(OH)D levels are more frequent in obese 
persons, suggesting that 25(OH)D deficiency is associ-
ated with obesity and vice versa.29–33 Obesity as measured 
by body mass index (BMI) above 30 kg/m2 has been 
positively associated with CM risk in males, but results 
for women are ambiguous and possibly confounded 
by personal habits as obese women may refrain from 
sunseeking behaviour compared with their normal-weight 
peers.11 Further, diet-induced obesity has been found to 
increase CM progression in mice models.34 The biolog-
ical mechanism underlying an obesity-induced increase 
in CM incidence is not well understood, although 
a hyperglycaemia hypothesis has been suggested.35 
Another hypothesis suggests that adipocytes produce 
high levels of vascular endothelial growth factor, associ-
ated with visceral fat, which contributes to angiogenesis 
and tumour growth.36
The metabolic hormone leptin may be a risk factor 
for both CM and CM progression. Leptin is released 
by adipose tissue and plays an important role in the 
regulation of insulin sensitivity and weight regula-
tion.37 38 Increased diagnostic serum levels of leptin have 
been associated with increased CM risk, possibly caused by 
a leptin-induced increase in neoangiogenesis, reduction 
of melanogenesis and a decreased capacity of the melano-
cytes’ DNA repair.39 40 Recent studies have demonstrated 
that leptin receptors are present in melanoma cell lines 
that proliferate in response to leptin, and that leptin 
bound to its receptor stimulates melanoma growth.41–44
After a CM diagnosis, there is an increased risk of diag-
nosis of additional CM, as well as other cancers.45 46 For 
example, the risk of lymphoma before or after CM has 
received increased focus.47 Immune perturbation has 
been suggested to contribute to the development of CM 
after non-Hodgkin’s lymphoma (NHL) subtypes such 
as chronic lymphocytic leukaemia/small lymphocytic 
lymphoma.48 As for CM, low 25(OH)D serum levels have 
also been associated with reduced survival and poor prog-
nosis after NHL,49 50 which raises the question of whether 
low 25(OH)D could alter the risk of lymphoma as a 
second cancer after CM or vice versa.
Aims and hypotheses
The interplay between 25(OH)D and obesity and 
their relation to CM is poorly described, and increased 
knowledge of these factors is warranted to improve CM 
prevention and prognosis. In the present study protocol, 
we propose a set of prospective cohort and nested case–
control studies with the primary aim of examining BMI 
and serum levels of 25(OH)D and leptin in relation to 
CM risk, Breslow thickness and mortality, and risk of 
second cancer and survival after a CM diagnosis. As a 
secondary aim, we propose a nested case–control study 
of lymphoma risk after CM and vice versa, in relation to 
serum levels of 25(OH)D and leptin.
We hypothesise that:
1. High prediagostic BMI (≥30 kg/m2, quantiles, 
continuous) is associated with
 ► Increased CM risk, Breslow thickness and 
mortality;
 ► Reduced survival after a CM diagnosis;
 ► Increased risk of contracting CM followed by a 
second cancer (n=292 851);
 ►  Increased risk of second cancer among CM 
survivors (n ≈ 3000).
2. High prediagnostic serum levels of leptin (>4 ng/mL, 
highest quantile, continuous) and low prediagnostic 
25(OH)D levels (<30 nmol/L, lowest quantile, 
continuous) are associated with
 ► Increased CM risk and Breslow thickness;
 ► Reduced survival after a CM diagnosis;
 ► Increased risk of contracting CM followed by a 
second cancer compared with no cancer history;
 ► Increased risk of second cancer among CM 
survivors;
 ► Increased lymphoma risk after a CM diagnosis 
and vice versa compared with no cancer history.
Methods And AnAlysIs
study population and data sources
Janus Serum Bank Cohort
This project is based on the Janus Serum Bank Cohort, a 
population-based biobank for prospective cancer studies 
containing serum samples and questionnaire data from 
292 851 Norwegians who participated in five health 
surveys 1972–2003. A detailed description of the Janus 
Serum Bank Cohort (hereafter Janus Cohort), its data 
and establishment, is published elsewhere.51 The Janus 
Cohort includes participants from the following surveys:
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Figure 1 Overview of linkage between different data sources. BMI, body mass index; ERY, erythemally weighted UVR; PIN, 
personal identification number; UVR, ultraviolet radiation.
1. The Oslo Study I (1972–1973) invited men residing in 
Oslo aged 20–49 years.
2. The Norwegian Counties Study was carried out as a 
three-wave survey (1974–1978, 1977–1983 and 1985–
1988), inviting men and women aged 20–49 years 
residing in Finnmark, Oppland or Sogn og Fjordane.
3. Oslo Age 40 Programme invited men and women 
aged 40 residing in Oslo 1981–1999.
4. The National Age 40 Programme triennially invited 
all men and women aged 40–42 years in all Norwegian 
counties during 1985–1999.
5. The TROFINN Health Study invited all men and 
women aged 30–75 years residing in Troms and 
Finnmark in 2001–2003.
Blood serum samples
The Janus Cohort has detailed sample information 
including date of sample collection and county of resi-
dence at sample collection. The samples have been stored 
at –25°C for up to 43 years.51 Serum samples of 25(OH)D 
and leptin have been demonstrated to have high stability 
after long-term storage,52 53 and previous studies have 
shown that serum from the Janus Cohort is well suited 
for analyses of 25(OH)D54 55 and leptin.56 57 Although 
the storage condition at −25°C is not ideal, a possible 
time-dependent degradation may be partly compensated 
for by matching cases and controls on time of blood draw.
Height and weight measurements and questionnaire data
Together with blood sample collection, standardised 
height and weight measurements were taken by trained 
personnel. Participants in the surveys were also asked 
to complete questionnaires on smoking habits, alcohol 
consumption, diet, physical activity, use of medications 
etc. Slightly different questionnaires (different wording 
and number of response categories) were used in the five 
health surveys, and a set of variables has been harmon-
ised.58 For the present project, the following variables are 
available: height (cm), weight (kg), BMI (kg/m2 and cate-
gorised as 12–18.49, 18.5–24.9, 25.0–29.9, ≥30),59 smoking 
status (never, former, current), cigarettes per day (1–9, 
10–14, ≥15), years of smoking (1–9, 10–29, ≥30), time 
since smoking cessation (<3 months, 3 months–1 year, 
1–5 years, >5 years), level of total physical activity (inac-
tive, low, medium, high) and level of physical activity at 
work (sedentary, walking, walking and lifting, heavy phys-
ical work).
Linking the Janus Cohort to population-based registries
Every resident in Norway is assigned a unique 11-digit 
personal identification number (PIN), which ensures a 
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Figure 2 Overview of study samples and overlap between cases and controls between studies.
correct linkage of the Janus Cohort to population-based 
registries and databases as described below and in figure 1.
Population-based registries
The Cancer Registry of Norway (CRN) has registered all 
new cancer diagnoses in Norway since 1953. Reporting 
of incident cancers to the CRN is compulsory by law, and 
information from pathologists, general practitioners, the 
Norwegian Patient Registry and the Norwegian Cause 
of Death Registry ensures a high degree of complete-
ness (overall 98.8%).3 For the present project, incident 
cancers from 1972 through 2014 will be linked to the Janus 
Cohort. The following cancer information will be used: 
date of diagnosis (month and year), tumour localisation 
(International Classification of Diseases seventh revision 
(ICD-7 codes) converted into ICD-10 codes), histology 
(codes from ICD-Oncology second and third revisions), 
clinical stage (local=no metastases, regional=metastasis in 
regional lymph nodes or surrounding area, distant=dis-
tant metastasis) and Breslow thickness (mm).
Date and cause of death (death from cancer and death 
from causes other than cancer) will be obtained from the 
Cause of Death Registry and vital status (alive, emigrated 
or dead) with corresponding dates will be obtained from 
the National Population Registry.
Data on occupation at baseline (categorised as indoor/
outdoor/mixed and high risk/medium risk/low risk for 
UVR exposure) and highest attained educational level at 
baseline (none, compulsory, upper secondary, college/
university) will be obtained from Statistics Norway.
UVR exposure matrices
County-specific, yearly average doses of ultraviolet A 
(UVA), ultraviolet B (UVB) and erythemally weighted 
UVR (ERY) will be calculated and assigned to each 
participant, according to place of residence, at baseline 
and cumulated throughout follow-up (ie, until cancer, 
emigration, death or 31 December 2014, whichever 
occurs first). The UVR exposure matrices will be based 
on measurement data from UV-network stations oper-
ated by the Norwegian Radiation Protection Authority 
and on modelled values as described by Medhaug et al.60 
Furthermore, age-specific, county-specific and time peri-
od-specific data on sunburns, sunbathing vacations and 
solarium (women only) use will be linked to the Janus 
Cohort on a group level as derived from questionnaire 
data collected in the Norwegian Women and Cancer 
study.61 62 Surveys conducted by the Norwegian Cancer 
Society show small gender differences with respect to 
frequency of sunburns and sunbathing vacations among 
Norwegian women and men.63 This is also supported by 
almost identical CM incidence rates between men and 
women in Norway in the past 60 years.64
study designs
Study I: a prospective cohort study
In a prospective cohort study among all 292 851 individ-
uals in the Janus Cohort (study sample I in figure 2), we 
will explore baseline BMI in relation to CM risk, Breslow 
thickness and mortality (hypothesis 1.1), survival after a 
CM diagnosis (hypothesis 1.2) and risk of second cancer 
after CM (hypotheses 1.3 and 1.4). Hypotheses 1.3 and 1.4 
differ by use of study sample; hypothesis 1.3 includes all 
292 851 individuals in the Janus Cohort, while hypothesis 
1.4 includes only the 3000 CM cases. Sex-specific analyses 
exploring the potential confounding effects from age, 
UVR exposure, smoking and education will be conducted 
for all analyses in study I.
Studies II–IV: prospective nested case–control studies
Three prospective case–control studies will be nested 
within the Janus Cohort (study samples II–IV in figure 2). 
For serum analyses, the nested case–control design is 
cost-efficient compared with the cohort design as only 
a limited number of CM cases and cancer-free controls 
are selected and matched using an incidence-density 
sampling scheme.65 Also, the nested case–control design 
takes advantage of the prospective nature of the cohort 
study by using data and serum samples collected before 
any cancer diagnosis, thereby reducing the potential for 
bias. Table 1 gives a complete description of the case, 
control and matching criteria.
Study II
Study II will examine CM risk and Breslow thickness 
according to prediagnostic serum levels of 25(OH)
D and leptin (hypothesis 2.1). We will study CM cases 
(II a; figure 2) without a history of cancer and controls 
alive and without a cancer history at the time of the case 
diagnosis (II b). We will include one control per case, 
matched on sex, age at serum sampling and season due 
to seasonal variation in 25(OH)D levels (table 1). UVR 
exposure, smoking and education will be adjusted for. 
Survival analysis (as in study I) will be undertaken on 
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Table 1 Overview of case, control and matching criteria for studies II–IV
Study II Study III Study IV
Case criteria
  Cases (n) 700 345 60
  Verification Histologically or 
cytologically verified 
CM in the Janus Cohort 
(ICD-10: C43).
Histologically or cytologically verified second 
cancer after CM in the Janus Cohort (ICD-10: 
C43 + any type).
Histologically or 
cytologically verified 
CM+lymphoma+CM in 
the Janus Cohort
(ICD-10:
C43 + ICD-O-3* or
ICD-O-3* + C43)
  Definition CM cases without a 
cancer history (not tied 
on date with another 
diagnosis)
Second cancers (any type) after first primary CM 
diagnosis
Lymphoma after first 
primary CM diagnosis or 
vice versa
  Selection Sampled at random 
from a pool of available 
CM cases
All available cases from study II + randomly 
sampled from CM pool
All available cases 
from study III and IV + 
randomly sampled from 
pool
  Age at diagnosis <75 years
  Year of diagnosis <2009
  Minimum time 
from blood draw to 
diagnosis
2 years
  Sex Male or female
Control criteria
  Control group II b III b III c IV b
  Controls (n) 700 345 345 180
  Definition† Alive, resident in 
Norway and no cancer 
history before case 
diagnosis
Alive, resident in Norway 
and no cancer history 
before diagnosis of 
second cancer
Alive, resident in Norway 
and a CM diagnosis 
but no second cancer 
before diagnosis of 
second cancer
Alive, resident in Norway 
and no cancer history 
before case diagnosis
  Selection Random sampling with replacement from a pool of available controls
Matching criteria
  Sex Same sex as case
  Age at blood draw ±2 years from age of case at blood draw. Stepwise extension by ±3 months up to ±3 years if 
necessary
  Time period of blood 
draw
The following 3-month intervals: (a) December–February, (b) March–May, (c) June–August, (d) 
September–November
  Date of CM diagnosis Only applies to control group III c: ±6 months. Stepwise extension by ±1 months up to ±1 year if 
necessary.
*9727, 9728, 9729, 9835, 9836, 9837, 9670, 9823, 9731, 9734, 9732, 9733, 9675, 9678, 9679, 9680, 9684, 9591, 9760, 9671, 9761, 9762, 
9673, 9690, 9691, 9695, 9698, 9687, 9826, 9689, 9699, 9764, 9700, 9701, 9709, 9718, 9708, 9702, 9705, 9714, 9716, 9717, 9948, 9719, 
9827, 9831, 9834 9833, 9940, 9820, 9832 9590, 9750.
†Allow only common cancers (colon, breast, prostate, skin and lung only) after date of diagnosis of case to conserve sera of rare cancers for 
later studies.
CM, cutaneous melanoma; ICD-10, International Classification of Diseases, 10th revision.
the subsample of CM cases (II a) with measured 25(OH)
D and leptin (hypothesis 2.2). Covariates included in 
study I will be taken into account.
Study III
In study III, we will examine the risk of second cancer 
after a CM diagnosis according to prediagnostic 
serum levels of 25(OH)D and leptin (hypotheses 
2.3 and 2.4). CM cases with a second cancer (III 
a; figure 2) and controls without a cancer history at 
the time of the second cancer diagnosis (III b) will 
be selected to address hypothesis 2.3. For hypoth-
esis 2.4, controls with a CM diagnosis at the time of 
the second cancer diagnosis will be selected (III 
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Table 2 Smallest detectable OR (above the null) according 
to proportion of controls exposed to low vitamin D (25(OH)
D) and high leptin levels, using a power of 0.80 and a 
significance level of 0.05
Proportion 
of exposed 
controls
Study II
Cases=700, 
ratio=1:1
Study III
Cases=345, 
ratio=1:1
Study IV
Cases=60, 
ratio=1:3
5%* 1.82 2.26 3.81
30%† 1.37 1.57 2.34
20%‡ 1.43 1.65 –
*Exposure = 25(OH)D <30 nmol /L.
†Exposure = 25(OH)D <50 nmol /L.
‡Exposure = high serum leptin levels ≥4.1 ng/mL).
25(OH)D, 25-hydroxyvitamin D.
c). We will include one control per case, matched 
on sex, age at serum sampling and season of serum 
sampling (table 1). In addition, control group III c 
will be matched on date of the CM diagnosis (table 1). 
Covariates included in studies I–II will be taken into 
account.
Study IV
A group including cases (IV a; figure 2) with CM before 
lymphoma or vice versa and controls (IV b) with no 
cancer history at the time of the second cancer diagnosis 
will be examined according to prediagnostic serum levels 
of 25(OH)D and leptin (hypothesis 2.5). All case–control 
pairs will be matched on sex, age at serum sampling and 
season of serum sampling (table 1). Covariates included 
in studies I–III will be taken into account.
Power and sample size calculations
Study I
With the large study sample (n=292 851), including more 
than 3000 CM cases by 31 December 2014, we have suffi-
cient statistical power to reveal minor risk differences 
between the BMI categories, normal weight (18.5–24.9 kg/
m2), overweight (25–29.9 kg/m2) and obese (≥30 kg/m2). 
Thus, further power calculation is not conducted.
Studies II–IV
Study II will include 700 CM cases of the approximately 
3000 available. Study III will include 345 cases with a 
second primary cancer after CM and study IV will include 
60 cases of lymphoma after CM or vice versa, which 
were the total number of cases in the Janus Cohort by 
31 December 2014. Table 2 shows the smallest detectable 
OR according to assumed proportion of controls exposed 
to low serum levels of 25(OH)D and high leptin levels 
when using a power of 0.80 and a significance level of 
0.05. The assumed proportions of exposed controls were 
based on previous studies conducted on serum samples 
from the Janus Cohort. For 25(OH)D, a study on prostate 
cancer reported that 4.4% and 30.6% of the controls had 
25(OH)D levels below 30 nmol/L and 50 nmol/L, respec-
tively.54 For leptin, a study on colon cancer reported that 
20% of the controls had a leptin level of 4.1 ng/mL or 
higher.56
data management
Case–control selection
As indicated in figure 2, there will be some overlap 
between cases and controls between the studies. CM cases 
(II a) will be sampled at random from all available CM 
cases in the Janus Cohort, independent of second cancer 
status. However, some of the CM cases (II a) may have 
developed a new cancer and then be eligible for use in 
study III as CMs with a second cancer (III a). Controls 
(II b) will be sampled at random with replacement (inci-
dence-density sampling) from the Janus Cohort and 
matched to CM cases (II a). Also, controls (II b) matched 
to the CM cases (II a) who developed a second cancer (III 
a) will be eligible for use in study III (group III b) if they 
are alive, resident and cancer-free at the time of the CM 
cases’ second cancer (III a). Cases from study II (II a) may 
be reused as controls in study III (III c) if they fulfil the 
matching criteria (table 1). The remaining case–control 
pairs for study III will be sampled from the Janus Cohort. 
Study IV will follow the same approach as studies II and 
III with respect to reuse. A picking list of unique serum 
samples for all studies will be prepared by a data manager 
for the Janus Serum Bank Cohort laboratory team.
Laboratory analyses
The Janus Serum Bank laboratory team will send 220 µL 
aliquots of serum to the Hormone Laboratory at Oslo 
University Hospital for analyses of 25(OH)D and leptin. 
The laboratory participated in the Vitamin D External 
Quality Assessment Scheme for total 25(OH)D. The 
Hormone Laboratory is accredited by the Norwegian 
Accreditation as a testing laboratory and complies with 
the requirements of the NS-EN ISO/IEC 17025 standards.
Serum concentrations of 25(OH)D will be determined 
by an in-house developed liquid chromatography/tandem 
mass spectrometry method. In brief, after protein precip-
itation, 25(OH)D will be extracted from samples using 
phospholipid depletion plates. Separation is achieved 
by reversed-phase chromatography and the isobaric C3 
epimer 3-epi-25(OH)D3 will be separated from 25(OH)
D3. Mass spectrometric detection will be performed 
by electrospray ionisation and triple quadruple ion 
separation (multiple reaction monitoring).66 Serum 
concentrations of leptin will be determined by using EMD 
Millipore Human Leptin Radioimmunoassay as described 
in Lee et al.67
Hormone Laboratory staff will be blinded to case–
control status. Two identical quality control (QC) samples 
with serum from a pool of several persons will be placed 
on each batch. These two QC samples will change posi-
tion for each new batch to avoid bias from weak spots 
in the machine/kit and will thus take into account both 
inter-batch variability and intra-batch variability. Each 
case–control pair will be placed and analysed on the same 
batch.
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statistical methods
In the cohort studies, we will use Poisson and Cox 
regression and estimate relative risks with 95% CIs. 
Spline models will also be explored if a non-linear rela-
tionship between exposure and outcome is assumed. 
In the nested case–control studies, conditional logistic 
regression will be applied to estimate ORs with 95% 
CIs. A multilevel approach will be applied for analyses 
containing group-level data. Directed acyclic graphs 
will be used in the process to select variables to include 
in the statistical models. Confounding variables will be 
included in the models and tests of interaction effects 
will be performed when relevant. In the case of interac-
tion effects, stratified results will be presented. All tests 
will be two-sided and p<0.05 will be considered statisti-
cally significant. All statistical analyses will be performed 
using Stata.
Analysis plan
We plan to conduct the following analyses to test our 
hypotheses:
 ► Hypothesis 1.1: A prospective cohort analysis of 
prediagnostic BMI and other anthropometric 
measures in relation to CM risk, Breslow thickness 
and mortality using the complete Janus Cohort 
(n=292 851).
 ► Hypothesis 1.2: A prospective analysis of survival 
after a CM diagnosis, according to prediagnostic 
BMI (n ≈ 3000).
 ► Hypothesis 1.3: A prospective cohort analysis of 
prediagnostic BMI and the risk of second cancer 
after a CM diagnosis using the complete Janus 
Cohort (n=292 851).
 ► Hypothesis 1.4: A prospective cohort analysis of 
prediagnostic BMI and the risk of second cancer 
among CM survivors (n ≈ 3000).
 ► Hypothesis 2.1: A nested case–control analysis of CM 
risk and Breslow thickness according to prediagnostic 
serum levels of 25(OH)D and leptin in 700 pairs.
 ► Hypothesis 2.2: A prospective analysis of survival after 
a CM diagnosis (n=700) according to prediagnostic 
serum levels of 25(OH)D and leptin.
 ► Hypothesis 2.3: A nested case–control analysis of risk 
of second cancer after a CM diagnosis according to 
prediagnostic serum levels of 25(OH)D and leptin. 
Using 345 pairs of cases with CM + a second cancer 
and controls without a cancer history.
 ► Hypothesis 2.4: A nested case–control analysis of risk 
of second cancer among CM survivors according to 
prediagnostic serum levels of 25(OH)D and leptin. 
Using 345 pairs of cases with CM + a second cancer 
and controls with a CM diagnosis.
 ► Hypothesis 2.5: A nested case–control analysis 
investigating risk of lymphoma after CM or vice versa 
according to prediagnostic serum levels of 25(OH)
D (n=60 cases) compared with controls without a 
cancer history.
Project strengths and limitations
A major strength of the project is the linkage of multiple 
data sources by use of the PIN, thereby establishing a 
comprehensive research file with independently and 
prospectively collected data, and a complete control of 
loss to follow-up. An important strength is also the use 
of high-quality cancer data with over 3000 CM cases 
from a population-based registry relying on compulsory 
reporting of incident cancers. Further, the prediagnostic 
serum samples assure a clear prospective temporal rela-
tionship between exposure and cancer, which limits the 
possibility of reverse causality, that is, that the cancer or 
its precursor affects the 25(OH)D or leptin serum levels.
An important limitation of the project is that we will 
only be able to obtain group-level data on UVR exposure 
(ambient UVA, UVB and ERY; sunburns, sunbathing vaca-
tions and solarium use), but our data will capture variation 
in these variables by age, time period and between coun-
ties. However, the long and complete time series, covering 
the whole observation period and early childhood for 
many of the participants, enables analysis with time-varying 
UVR exposure. Another limitation is the lack of data on 
pigmentary characteristics and number of naevi. Also, 
differences in skin colour between cases and controls could 
potentially bias our estimates. However, the average frac-
tion of non-whites during 1970–1991 (when 97% of the 
Janus Cohort was established) was less than 1% of the total 
Norwegian population,68 and hence we consider the risk of 
introducing bias by not taking individual information on 
skin colour into account as negligible.
ethIcs And dIsseMInAtIon
The project has a running approval from the Regional 
Committee for Medical and Health Research Ethics to 
link the different population-based registries to establish 
a deidentified research file. In addition, each registry 
and data source has approved that its data will be linked 
and used in a deidentified research file. A linkage key 
consisting of the 11-digit PIN and a project-specific ID 
number will be stored and governed by a third party 
unavailable to the research team. Moreover, participa-
tion in each of the health surveys constituting the Janus 
Cohort was voluntary and based on informed consent.
All results will be published in relevant peer-reviewed 
international scientific journals and presented at confer-
ences, nationally and internationally. Results will also 
be directly communicated to user groups such as the 
Norwegian Cancer Society, The Norwegian Melanoma 
Association, and to health authorities and clinicians. Both 
the annual Norwegian conferences (‘Oncologic Forum’, 
the Norwegian Melanoma Group Meeting) and interna-
tional conferences will serve as platforms for knowledge 
distribution to clinicians and researchers. Important 
results will also be disseminated through press releases. 
Further, lectures, the CRN website, social media and 
other potential channels will also be used to reach patient 
organisations, patients and the general public.
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